Development ofMB-2003, a novel monoclonal antibody (mAB) based countermeasure with antiviral activity against Ebola virus

Project: Research project

Project Details

StatusFinished
Effective start/end date4/19/16 → 5/31/17

Funding

  • Mapp Biopharmaceutical, Inc.: $558,281.00